US Patent 11912750 GDNF fusion polypeptides and methods of use thereof
Patent 11912750 was granted and assigned to Keros Therapeutics on February, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+19 properties)
Article (+515 characters)
US Patent 11912750 GDNF fusion polypeptides and methods of use thereof
Article
Patent abstract
The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jasbir S. Seehra0
Jennifer Lachey0
Date of Patent
February 27, 2024
0Patent Application Number
163489820
Date Filed
November 9, 2017
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11912750 GDNF fusion polypeptides and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
